Leukemia & Lymphoma

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	44
Impact of SF3B1 mutation in myelofibrosis	37
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	36
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	27
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	27
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	25
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	23
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	23
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	23
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	23
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	22
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans	21
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	21
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	21
Organ toxicities associated with chimeric antigen receptor T-cell therapy	20
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	20
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	19
XX International workshop on chronic lymphocytic leukemia	19
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	18
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	18
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	17
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	17
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	16
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	16
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	16

Transplantation provides superior survival high risk myeloid malignancies in older patients	16
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	15
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	15
Management of relapsed/refractory mantle cell lymphoma	14
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	14
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	14
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	14
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	14
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	14
Hypereosinophilia after CAR T-cell therapy	14
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	14
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	13
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	13
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	13
T-cell/histiocyte-rich large B-cell lymphoma, insights into prognosis and treatment complexity in the context of immunotherapeutics	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	12
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	12
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	12
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	12
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	12
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	12
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	12
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	12
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	12
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	11
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	11
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	11
Homocysteine-driven oxidative stress in pediatric lymphoma: a cross-sectional study of metabolic and genetic modulators	11
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	11
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	11
Donor-derived somatic genetic rescue with prolonged hematopoietic stability following sibling allogeneic stem cell transplant in SAMD9 syndrome	11
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	11
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	11
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	11
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	11
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	11
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	11
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	10
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia	10
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	10
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	10
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Correction	10
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	10
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	10
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	10
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	10
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	10
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	10

COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	10
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	10
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	10
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	9
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	9
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	9
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	9
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	9
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	9
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	9
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Prospects for liquid biopsy approaches in lymphomas	9
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	9
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Mitigating time toxicity in lymphoma and multiple myeloma	8
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	8
Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients	8
[ 211 At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	8
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	8
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	8
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	8
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	8
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	8
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	8
Emerging drug profile: JAK inhibitors	8
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	8
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	8
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	8
Factors associated with long-term quality of life after allogenic stem cell transplantation	8
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase	8
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	7
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	7
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	7
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Sepsis and mucositis-related biomarkers in adult hematologic patients with febrile neutropenia	7
Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia	7
CALR -mutated myeloproliferative neoplasms	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence	7
XXI International Workshop on CLL 2025	7
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	7
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	7
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	7
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	7
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives	7
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Recipient polymorphism of the C-reactive protein (CRP) gene rs2794521 stratified disease-free survival, but did not influence maximum serum CRP levels during neutropenia after single-unit cord blood t	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	7
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	7
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7
Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1 -positive AML: results from AML-CAMS seria	7
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6

Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Follicular lymphoma: an update on biology and optimal therapy	6
Leukocytosis and MPNs: Where do we stand?	6
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	6
Correction	6
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Correction	6
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	6
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data	6
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	6
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old	6
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	6
Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation	6
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort	6
Lineage switch from B-ALL to AML via an intervening MDS/MPN phase with acquisition of RBM15::MKL1 and RAD21	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
Daratumumab bortezomib and dexamethasone in transplant ineligible newly diagnosed elderly myeloma patients (AMN006)—a trial by Asian Myeloma Network (NCT03695744)	6
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape	5
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings	5
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience	5
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	5
Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse	5
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study	5
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCT	5
CD19 CAR-T induces complete and durable remission in cold agglutinin syndrome associated relapse and refractory diffuse large B cell lymphoma	5
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States	5
Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy	5
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Correction	5
Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas	5
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond	5
Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML	5
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data	5
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	5
Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)	5
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	5
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10	5
Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5